Catalio Capital Management, LP is a New York-based multi-strategy investment firm that specializes in breakthrough biomedical technology and innovative healthcare companies worldwide. Their private equity strategy focuses on investing in privately held biomedical technology companies at all stages, while their structured opportunities strategy provides senior-secured financing to these companies. Additionally, their public equities strategy is a long bias, fundamental, bottoms-up equity long-short strategy that invests in global healthcare equities across sectors, including innovative drugs, devices, diagnostics, and data. Catalio also offers co-investment vehicles that provide direct access to their best deals.
Founded in 2020 by George Petrocheilos and R. Jacob Vogelstein, Catalio aims to produce extraordinary returns by creating and sustaining life sciences companies that combine the best science and technology with exceptional management and execution. They work closely with Catalio Venture Partners, an elite group of world-class scientists, engineers, and clinicians, to identify breakthrough biotechnologies and co-invest with top-tier funds. With a focus on next-generation drugs, devices, diagnostics, data, tools, and healthcare services, Catalio works closely with each portfolio company to build and grow the business from inception to exit. Their team comprises investment professionals and world-renowned, serial scientist-entrepreneurs with a proven track record in starting up and spinning out category-defining businesses in the life sciences.
Generated from the website
